中药复方治疗糖尿病随机对照试验的报告质量:基于CONSORT及其中药复方扩展版
结果显示总体依从率分别为53.56%和45.71%,中药复方扩展版依从性更差,尤其中医证型披露不足。
要点
- 中药复方治疗糖尿病RCT对CONSORT声明平均依从率为53.56%。
- 对CONSORT中药复方扩展版平均依从率为45.71%,中医证型报告不足。
- 多中心和大样本作者数量与较好报告质量相关。
核心结论
- 中药复方治疗糖尿病RCT的报告质量仍不理想,对CONSORT中药复方扩展版的依从性更差。
研究设计与样本
- 依据CONSORT声明及其中药复方扩展版计算总体依从比例,并分析预设研究特征与报告质量的关联。
主要发现
- 对CONSORT中药复方扩展版的平均依从率为45.71%。
- 多中心和大作者数量与基于CONSORT声明的报告质量关联最强。
- 对中药复方扩展版的依从性普遍不足,尤其体现在中医证型披露方面。
关键数值与推荐
- 报告质量评估采用CONSORT声明及其中药复方扩展版,总体依从率分别表达为53.56%和45.71%。
临床怎么用
- 作者和编辑在报告中药复方治疗糖尿病的RCT时应遵循CONSORT声明及其中药复方扩展版。
- 建议倡导甚至强制要求遵守CONSORT声明及其中药复方扩展版,以确保报告透明规范。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This study aimed to assess the overall reporting quality of randomized controlled trials (RCTs) in Chinese herbal medicine (CHM) formulas for patients with diabetes, and to identify factors associated with better reporting quality. Methods: Four databases including PubMed, Embase, Cochrane Library and Web of Science were systematically searched from their inception to December 2022. The reporting quality was assessed based on the Consolidated Standards of Reporting Trials (CONSORT) statement and its CHM formula extension. The overall CONSORT and its CHM formula extension scores were calculated and expressed as proportions separately. We also analyzed the pre-specified study characteristics and performed exploratory regressions to determine their associations with the reporting quality. Results: Seventy-two RCTs were included. Overall reporting quality (mean adherence) were 53.56% and 45.71% on the CONSORT statement and its CHM formula extension, respectively. The strongest associations with reporting quality based on the CONSORT statement were multiple centers and larger author numbers. Compliance with the CHM formula extension, particularly regarding the disclosure of the targeted traditional Chinese medicine (TCM) pattern (s), was generally insufficient. Conclusion: The reporting quality of RCTs in CHM formulas for diabetes remains unsatisfactory, and the adherence to the CHM formula extension is even poorer. In order to ensure transparent and standardized reporting of RCTs, it is essential to advocate for or even mandate adherence of the CONSORT statement and its CHM formula extension when reporting trials in CHM formulas for diabetes by both authors and editors.
引用
- Liu Y, Hu C, Zhou K, et al. The reporting quality of randomized controlled trials in Chinese herbal medicine (CHM) formulas for diabetes based on the consort statement and its extension for CHM formulas. Front Pharmacol. 2024. PMID: 38318135. doi:10.3389/fphar.2024.1288479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。